Fierce Pharma

FEBRUARY 20, 2024

After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. | Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany.

Manufacturing 264

Manufacturing 264

Salesforce

FEBRUARY 20, 2024

For many people, a sudden tingling in the leg or a feeling of numbness in the arm isn’t too much cause for alarm. The tingling or the numbness goes away after a little while, and they go on with their lives. But for Brooke Eby, an abrupt limp on her way to a conference one day ultimately led to a diagnosis of amyotrophic lateral sclerosis (ALS) at the age of 33.

Patients 137

Patients Pharma Leads Consulting 137

Fierce Pharma

FEBRUARY 20, 2024

AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive. | AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall.

Pharma 260

Pharma 260

pharmaphorum

FEBRUARY 20, 2024

The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).

FDA 116

FDA 116

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

FEBRUARY 20, 2024

On AbbVie’s latest earnings call, analysts were curious whether long-time CEO Richard Gonzalez was weighing a succession plan now that Humira’s loss of U.S. exclusivity has passed. | Robert Michael, AbbVie’s current president and chief operating officer, has been tapped by the company’s board of directors to take over Richard Gonzalez’s CEO post on July 1.

221

221

MedCity News

FEBRUARY 20, 2024

About 57% of patients have gone to a doctor’s appointment to discover that the provider was not the right one for their condition, according to new research from Zocdoc. Because of this, the company launched a new tool called Guided Search that helps pair patients with the correct provider.

Patients 109

Patients Healthcare Healthcare 109

PharmaVoice

FEBRUARY 20, 2024

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Marketing 104

Marketing Healthcare Healthcare 104

Fierce Pharma

FEBRUARY 20, 2024

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. | GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals who’ve faced issues adhering to their medications.

Patients 203

Patients Medical 203

MedCity News

FEBRUARY 20, 2024

There is growing and coordinated momentum behind the goal of ensuring connected medical devices improve people’s lives without introducing them to cybersecurity threats and associated safety risks. There also is a proven playbook for implementing the type of multi-layered, security-by-design strategies these initiatives advocate.

Safety 108

Safety Medical 108

Fierce Pharma

FEBRUARY 20, 2024

This week on “The Top Line,” we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled indiv | This week, we’re speaking with Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences about how advancements in HIV treatment research have enabled individuals to lead longer and healthier lives by taking and staying on medication.

Leads 161

Leads Medical 161

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Commerce

FEBRUARY 20, 2024

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

FDA 101

FDA 101

Fierce Pharma

FEBRUARY 20, 2024

AstraZeneca is celebrating a trio of recent advancements for its portfolio in non-small cell lung cancer (NSCLC). | AstraZeneca is celebrating a trio of advancements for its portfolio in non-small cell lung cancer, including an “overwhelming efficacy benefit” for Tagrisso in early-stage disease. Besides the trial result, AZ touted an FDA approval for Tagrisso's chemo combo in metastatic tumors, plus an application acceptance for a Daiichi Sankyo-partnered TROP2 antibody-drug conjugate in a

FDA 150

FDA Patients 150

MedCity News

FEBRUARY 20, 2024

There are plenty tools and data sharing standards available to foster a more cohesive and integrated approach to healthcare interoperability. However, providers aren’t really adopting these tools, experts said during a recent panel.

Healthcare 108

Healthcare Healthcare 108

Fierce Pharma

FEBRUARY 20, 2024

It’s been 15 years since Genzyme began rationing the Fabry disease treatment Fabrazyme after a shortage caused by contamination at a manufacturing site, marking the start of many years of litigatio | Sanofi's Genzyme was accused of causing injuries after contaminated doses of its Fabry disease drug led to a shortage, during which the company rationed the drug.

Manufacturing 140

Manufacturing 140

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

FEBRUARY 20, 2024

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s first-to-market Zeposia.

Marketing 115

Marketing 115

European Pharmaceutical Review

FEBRUARY 20, 2024

A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 million by 2029. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85 percent between 2022 and 2029. The rising productivity of cell lines has improved the performance of upstream processing with low cost and high process reproducibility, the report explained.

Marketing 98

Marketing Manufacturing Media Pharmaceutical 98

MedCity News

FEBRUARY 20, 2024

FDA’s regulation of single-use device reprocessing effectively made the U.S. the leader in EP sustainability efforts early on. However, very little has been done to build on this early leadership.

Healthcare 100

Healthcare Healthcare FDA 100

pharmaphorum

FEBRUARY 20, 2024

Bayer takes anti-alpha2 antiplasmin antibody BAY3018250 into phase 2 as a deep vein thrombosis treatment, hoping to improve on thrombolytics.

115

115

Advertisement

MedCity News

FEBRUARY 20, 2024

Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS. But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target.

Leads 100

Leads Biopharma Pharma 100

pharmaphorum

FEBRUARY 20, 2024

Google DeepMind and Owkin scientists have joined forces to create Bioptimus, an AI startup that aims to develop a foundation model for biology

115

115

MedCity News

FEBRUARY 20, 2024

The FDA clinical hold follows a patient death from liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule.

FDA 99

FDA Patients Safety Biopharma 99

Pharmaceutical Technology

FEBRUARY 20, 2024

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Food 94

Food FDA 94

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

FEBRUARY 20, 2024

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Healthcare 98

Healthcare Healthcare Medical 98

PharmaVoice

FEBRUARY 20, 2024

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

Competition 69

Competition Manufacturing 69

MedCity News

FEBRUARY 20, 2024

The conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, is the premier boutique healthcare investment event in the U.S.

Healthcare 92

Healthcare Healthcare 92

PharmaTimes

FEBRUARY 20, 2024

The nanogels, in combination with rolipram, contributed to the recovery of injured tissue

98

98

Advertisement

Distribution

pharmaphorum

FEBRUARY 20, 2024

AbbVie reveals its CEO succession plan, as COO Robert Michael prepares to take over from Richard Gonzalez on July 1

103

103

Evolve Your Success

FEBRUARY 20, 2024

In the dynamic realm of medical device sales, the possibilities are limitless. Dive into the role of a Diabetes Sales Specialist and explore the diverse opportunities that await. In this episode for Black History Month, Samuel Adeyinka interviews District Sales Trainer & Diabetes Sales Specialist, O’Neal Ford , to shed light on his role. Discover the importance of curiosity and adaptability in the field as O’Neal discusses the evolving landscape of endocrinology and the impact of

Sales 59

Sales Medical sales Medical Management 59

PharmaTimes

FEBRUARY 20, 2024

The new programme will engage with children and young people under the age of 18 years

Patients 87

Patients 87

Clarify Health

FEBRUARY 20, 2024

Since July 2022, CMS has required most group health plans and issuers of group or individual health insurance to post price information for covered items and health services. For most, the concept of price transparency has been approached as a compliance necessity. However, it offers far more than just adherence to regulations. Price transparency stands as a strategic asset with the power to significantly help payers.

Competition 52

Competition Marketing Healthcare Healthcare 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales